Table 3.
Changes in N-QoL scores after 12 weeks treatment with prosultiamine
| Question | Before treatment | After treatment | P value |
|---|---|---|---|
| Q1 Concentration |
0.6 ± 1.0 |
0.3 ± 1.6 |
0.1235 |
| Q2 Low in energy |
0.9 ± 1.1 |
0.4 ± 0.6 |
0.0077 |
| Q3 Sleep during the day |
1.5 ± 1.4 |
1.0 ± 1.1 |
0.0229 |
| Q4 Productiveness |
0.7 ± 0.9 |
0.3 ± 0.6 |
0.0830 |
| Q5 Physical activities |
1.0 ± 1.2 |
0.5 ± 0.8 |
0.0505 |
| Q6 Fluid restriction |
0.8 ± 1.2 |
0.7 ± 0.9 |
0.3270 |
| Q7 Inadequate sleep at night |
1.6 ± 1.5 |
0.7 ± 1.0 |
0.0070 |
| Q8 Disturbance of others |
0.8 ± 1.9 |
0.5 ± 1.8 |
0.0277 |
| Q9 Preoccupation with waking at night |
0.6 ± 1.1 |
0.3 ± 0.6 |
0.1235 |
| Q10 Worry over condition worsening |
1.5 ± 1.5 |
0.8 ± 1.1 |
0.0032 |
| Q11 Worried over treatment options |
1.5 ± 1.6 |
1.0 ± 1.3 |
0.0303 |
| Q12 Overall bother |
1.3 ± 1.3 |
0.8 ± 0.8 |
0.0238 |
| Q13 Overall impact on everyday life |
2.6 ± 2.8 |
0.9 ± 1.0 |
0.0023 |
| Converted overall score (Q1 to 12) |
73.2 ± 21.0 |
85.3 ± 19.9 |
0.0001 |
| Subscale scores: |
|
|
|
| Sleep/Energy (Q1 to5, 7) |
74.0 ± 20.7 |
87.0 ± 15.0 |
0.0001 |
| Bother/Concern (Q6, Q8 to12) | 72.4 ± 25.7 | 83.7 ± 21.2 | 0.0028 |
Subjective symptoms were evaluated using the scores of the Nocturia Quality of Life (N-QoL) questionnaire [15-17]. The score ranges of each question except Q13 are from 0 to 4. The score of Q13 is from 0 to 10. Converted overall score (0–100) = 100 × total converted scores (Q1 to 12)/4 × question numbers, converted score = 4-each raw score. Subscale score (0 to 10) = 100 × total converted scores/4 × question numbers. Statistical significance was determined by the Wilcoxon signed-rank test.